Citizens Maintains Market Outperform on Microbot Medical, Lowers Price Target to $2
Benzinga Newsdesk 1 day ago
Analyst RatingsNewsPrice Target
This page contains a summary, not the full article. Continue to benzinga.com to read the original report.
Citizens analyst Daniel Stauder maintains Microbot Medical (NASDAQ:MBOT) with a Market Outperform and lowers the price target from $2.5 to $2.
Citizens analyst Daniel Stauder maintains Microbot Medical (NASDAQ:MBOT) with a Market Outperform and lowers the price target from $2.5 to $2.
